Valneva SE develops, manufactures and commercializes prophylactic vaccines for infectious diseases, with revenue from proprietary travel vaccines and a pipeline of vaccine candidates. News about VALN commonly covers clinical and regulatory developments for the Lyme disease vaccine candidate PF-07307405/LB6V, partnered with Pfizer, as well as Shigella, chikungunya and other infectious-disease programs.
Company updates also include commercial partnerships, licensing arrangements such as vaccine-antigen technology agreements, manufacturing and supply collaborations, marketing and distribution relationships, operating results, and capital actions tied to Valneva's vaccine portfolio and public-company status on Nasdaq and Euronext Paris.
Pfizer reported third-quarter 2021 revenues of $24.1 billion, a 134% increase year-over-year, driven by the success of the Comirnaty vaccine, which contributed $13 billion. Excluding Comirnaty, revenues still grew 7% to $11.1 billion. The reported diluted EPS was $1.42, with adjusted EPS at $1.34. Pfizer raised its full-year revenue guidance to $81-82 billion and adjusted EPS to $4.13-4.18. The company anticipates around $36 billion in revenue from Comirnaty for 2021, with plans to deliver 2.3 billion doses globally.